---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-062039"
form_type: "8-K"
ticker: "RXST"
cik: "0001111485"
company_name: "RxSight, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:04:48.450321+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# RxSight Q3 revenue up 76% to $22.2M; raises FY2023 guidance

## Summary
- Q3 revenue $22.2M (+76% YoY); net loss $(12.4)M, EPS $(0.35); adjusted net loss $(6.9)M, adj. EPS $(0.19)
- Sold 66 LDDs (installed base 589, +72% YoY); LAL procedure volumes 13,657 (+107% YoY)
- Raised FY2023 revenue guidance to $85-87M (prior $81-86M); gross margin guidance 60-61% (prior 58-60%)
- Eliminated remaining $20M term loan; expects to reduce annualized interest expense by ~$5.6M
- Raised $11.7M net via ATM facility; cash/short-term investments $131.9M at quarter end

## SEC filing metadata
- accession: 0000950170-23-062039
- form_type: 8-K
- ticker: RXST
- cik: 0001111485
- company_name: RxSight, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1111485/000095017023062039/0000950170-23-062039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1111485/000095017023062039/rxst-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-062039
- JSON: https://secwatch.observer/filing/0000950170-23-062039.json
- Plain text: https://secwatch.observer/filing/0000950170-23-062039.txt

## Key facts
- Earnings Releases
  RxSight, Inc. reported three and nine months ended September 30, 2023 results: revenue $22.2 million, net income $(12.4) million, EPS $(0.35) per basic and diluted share. Guidance raised.
  - Period: three and nine months ended September 30, 2023
  - Revenue: $22.2 million
  - Net income: $(12.4) million
  - EPS: $(0.35) per basic and diluted share
  - Guidance: raised
  - Result: reported results
  source text: cataract surgery, today reported financial results for the three and nine months ended September 30, 2023. Key Quarterly Highlights • Reported third quarter 2023 revenue of $22.2 million, an increase of 76% compared to the third quarter of 2022, reflecting: • The sale of 66 Light Delivery Devices (LDDTMs), representing a 35% increase in unit sales compared to the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1111485/000095017023062039/0000950170-23-062039-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.